MetLife stock (US59156R1086): Analyst upgrades fuel recovery after Q1 earnings beat

MetLife shares rebounded as JP Morgan and Keefe Bruyette & Woods raised price targets following first-quarter results that topped expectations, signaling operational strength in the insurance sector.

MetLife delivered a first-quarter earnings beat that has attracted fresh analyst attention, with two major banks raising their price targets within days of the results. The stock traded at $78.67 USD on May 13, 2026 on the New York Stock Exchange, according to GuruFocus as of May 13, 2026, recovering from an initial post-earnings dip.

On May 12, 2026, JP Morgan maintained its Overweight rating and raised its price target to $96.00, according to ad-hoc-news as of May 12, 2026. One day later, Keefe Bruyette & Woods analyst Ryan Krueger upgraded MetLife to Outperform and lifted the target from $87.00 to $98.00, reflecting a 12.64% increase, according to GuruFocus as of May 13, 2026.

As of: May 14, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: MetLife Inc.
• Sector/industry: Insurance (life, annuities, group benefits)
• Headquarters/country: United States
• Core markets: US, Asia, Latin America, EMEA
• Key revenue drivers: Life insurance, annuities, group benefits, retirement solutions
• Home exchange/listing venue: NYSE (MET)
• Trading currency: USD

MetLife: core business model

MetLife Inc. is one of the largest life insurance and employee benefits providers in the United States, serving millions of customers globally. The company operates across multiple segments including life insurance, annuities, group benefits, and retirement solutions. Its diversified revenue streams span individual life insurance products, workplace benefits for employers, and retirement income solutions, positioning it as a comprehensive financial services player in the insurance sector.

Q1 earnings beat and analyst momentum

MetLife's first-quarter results outperformed Wall Street expectations on both revenue and non-GAAP profit metrics, according to ad-hoc-news as of May 12, 2026. Despite the positive results, shares initially dipped from $80.16 to $78.30 immediately after the announcement, a typical post-earnings pullback. However, the subsequent analyst upgrades suggest confidence in the company's operational trajectory and earnings quality. The consensus analyst rating across major banks now stands at Overweight, with a mean price target of $92.73, according to FactSet data referenced in market reports.

Conclusion

MetLife's first-quarter earnings beat combined with rapid analyst upgrades from JP Morgan and Keefe Bruyette & Woods signals renewed confidence in the insurer's operational execution and earnings power. The stock's recovery from its post-earnings dip to trade near $79 reflects investor appetite for quality insurance exposure amid economic uncertainty. For US investors seeking dividend income and exposure to the insurance sector, MetLife's diversified business model and global reach provide a foundation for long-term portfolio positioning, though individual circumstances and risk tolerance should guide any investment decision.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.